Table 1.
Transcripts (CT) | ||||||||
---|---|---|---|---|---|---|---|---|
TNF-αR | Fn14 | IL-6R | TNF-α | TWEAK | IL-6 | TRIM63 | FBXO32 | |
CTRL | 22.46 ± (0.68) | 22.40 ± (0.63) | 22.42 ± (0.64) | 22.45 ± (0.67) | 22.19 ± (0.67) | 22.43 ± (0.74) | 22.03 ± (0.64) | 22.11 ± (0.66) |
SX | 22.55 ± (0.83) | 22.49 ± (0.84) | 22.53 ± (0.88) | 22.49 ± (0.86) | 22.25 ± (0.92) | 22.46 ± (0.89) | 22.13 ± (0.84) | 22.18 ± (0.84) |
SX Transcripts (CT) | TKA vs. THA | MuIS− vs. MuIS+ | Female vs. Male |
---|---|---|---|
TNF-αR | 22.47 ± (0.59); 22.72 ± (2.21) | 22.47 ± (0.91); 22.70 ± (0.64) | 22.54 ± (0.57); 22.57 ± (1.17) |
Fn14 | 22.37 ± (0.62); 22.75 ± (1.17) | 22.37 ± (0.87); 22.72 ± (0.73) | 22.47 ± (0.57); 22.52 ± (1.18) |
IL-6R | 22.41 ± (0.58); 22.78 ± (1.30) | 22.32 ± (0.90); 22.91 ± (0.71) | 22.52 ± (0.57); 22.53 ± (1.26) |
TNF-α | 22.36 ± (0.63); 22.78 ± (1.18) | 22.35 ± (0.89); 22.76 ± (0.74) | 22.52 ± (0.62); 22.44 ± (1.17) |
TWEAK | 22.05 ± (0.73); 22.69 ± (1.13) | 22.00 ± (0.90); 22.72 ± (0.76) | 22.26 ± (0.76); 22.24 ± (1.15) |
IL-6 | 22.29 ± (0.64); 22.83 ± (1.21) | 22.31 ± (0.89); 22.74 ± (0.84) | 22.43 ± (0.65); 22.49 ± (1.21) |
TRIM63 | 22.05 ± (0.57); 22.31 ± (1.24) | 22.12 ± (0.91); 22.16 ± (0.71) | 22.11 ± (0.57); 22.17 ± (1.18) |
FBXO32 | 22.08 ± (0.57); 22.39 ± (1.23) | 22.18 ± (0.90); 22.16 ± (0.71) | 22.17 ± (0.56); 22.18 ± (1.18) |
Values are means ± (SD). Housekeeping genes = GAPDH and C1orf43. Sample size: contralateral (CTRL)/surgical (SX) limbs = 70; total hip arthroplasty (THA) = 22; total knee arthroplasty (TKA) = 48; muscle inflammation susceptibility (MuIS)− = 46; MuIS+ = 24; female = 44; male = 26. FBXO32, muscle atrophy F-box (MAFbx); Fn14, fibroblast growth factor-inducible 14; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; TNF-α, tumor necrosis factor alpha; TNF-αR, tumor necrosis factor alpha receptor; TRIM63, muscle ring finger-1 (MuRF1); TWEAK, TNF-like weak inducer of apoptosis.